Off-label dermatologic uses of IL-17 inhibitors

References

• Blauvelt A, Chiricozzi A. The immunologic role of IL-17 in psoriasis and psoriatic arthritis pathogenesis. Clinic Rev Allerg Immunol. 2018;55(3):379–390.
   PubMed Web of Science ®Google Scholar
• Malakouti M, Brown GE, Wang E, et al. The role of IL-17 in psoriasis. J Dermatolog Treat. 2015;26(1):41–44.
   PubMed Web of Science ®Google Scholar
• Bissonnette R, Luger T, Thaci D, et al. Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate-to-severe psoriasis through 5 years of treatment (SCULPTURE Extension Study). J Eur Acad Dermatol Venereol. 2018;32(9):1507–1514.
   PubMed Web of Science ®Google Scholar
• Gordon KB, Colombel JF, Hardin DS. Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis. N Engl J Med. 2016;375(21):2102.
   PubMed Web of Science ®Google Scholar
• Puig L, Lebwohl M, Bachelez H, et al. Long-term efficacy and safety of brodalumab in the treatment of psoriasis: 120-week results from the randomized, double-blind, placebo- and active comparator-controlled phase 3 AMAGINE-2 trial. J Am Acad Dermatol. 2019;82(2):352–359.
   PubMed Web of Science ®Google Scholar
• Cosentyx® (secukinumab) [package insert]. Food and drug administration. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2015.
   Google Scholar
• Taltz® (ixekizumab) [package insert]. Food and drug administration. Indianapolis, IN: Eli Lilly and Company; 2016.
   Google Scholar
• Siliq® (brodalumab) [package insert]. Food and Drug Administration. Bridgewater, NJ: Valeant Pharmaceuticals North America; 2017.
   Google Scholar
• Matusiak Ł, Szczęch J, Bieniek A, et al. Increased interleukin (IL)-17 serum levels in patients with hidradenitis suppurativa: Implications for treatment with anti-IL-17 agents. J Am Acad Dermatol. 2017;76(4):670–675.
   PubMed Web of Science ®Google Scholar
• Feldmeyer L, Mylonas A, Demaria O, et al. Interleukin 23-Helper T cell 17 axis as a treatment target for pityriasis rubra pilaris. JAMA Dermatol. 2017;153(4):304–308.
   PubMed Web of Science ®Google Scholar
• Prussick L, Rothstein B, Joshipura D, et al. Open-label, investigator-initiated, single-site exploratory trial evaluating secukinumab, an anti-interleukin-17A monoclonal antibody, for patients with moderate-to-severe hidradenitis suppurativa. Br J Dermatol. 2019;181(3):609–611.
   PubMed Web of Science ®Google Scholar
• Marasca C, Megna M, Balato A, et al. Secukinumab and hidradenitis suppurativa: Friends or foes?. JAAD Case Rep. 2019;5(2):184–187.
   PubMedGoogle Scholar
• Thorlacius L, Theut Riis P, Jemec G. Severe hidradenitis suppurativa responding to treatment with secukinumab: a case report. Br J Dermatol. 2018;179(1):182–185.
   PubMed Web of Science ®Google Scholar
• Schuch A, Fischer T, Boehner A, et al. Successful treatment of severe recalcitrant hidradenitis suppurativa with the interleukin-17A antibody secukinumab. Acta Derm Venerol. 2018;98(1):151–152.
   PubMed Web of Science ®Google Scholar
• Jorgensen AR, Yao Y, Thomsen SF. Therapeutic response to secukinumab in a 36-year-old woman with hidradenitis suppurativa. Case Rep Dermatol Med. 2018;2018:8685136.
   PubMedGoogle Scholar
• Wain T, Choy B, Satchell AC, et al. Secukinumab in pityriasis rubra pilaris: a case series demonstrating variable response and the need for minimal clinical datasets. JAAD Case Rep. 2018;4(5):500–505.
   PubMedGoogle Scholar
• Bonomo L, Levitt JO. Secukinumab emerges as a rapidly effective therapy for pityriasis rubra pilaris. Cutis. 2018;101(5):367–369.
   PubMed Web of Science ®Google Scholar
• Schuster D, Pfister-Wartha A, Bruckner-Tuderman L, et al. Successful treatment of refractory pityriasis rubra pilaris with secukinumab. JAMA Dermatol. 2016;152(11):1278–1280.
   PubMed Web of Science ®Google Scholar
• Gauci ML, Jachiet M, Gottlieb J, et al. Successful treatment of type II pityriasis rubra pilaris with secukinumab. JAAD Case Rep. 2016;2(6):462–464.
   PubMedGoogle Scholar
• Di Scala G, Bettiol A, Cojan RD, et al. Efficacy of the anti-IL 17 secukinumab in refractory Behcet’s syndrome: a preliminary study. J Autoimmun. 2019;97:108–113.
   PubMed Web of Science ®Google Scholar
• Guttman-Yassky E, Nia JK, Hashim PW, et al. Efficacy and safety of secukinumab treatment in adults with extensive alopecia areata. Arch Dermatol Res. 2018;310(8):607–614.
   PubMed Web of Science ®Google Scholar
• Todberg T, Zachariae C, Krustrup D, et al. The effect of treatment with anti-interleukin-17 in patients with allergic contact dermatitis. Contact Dermatitis. 2018;78(6):431–432.
   PubMed Web of Science ®Google Scholar
• Cotter C, Tobin AM, O’Connor R, et al. Severe refractory hidradenitis suppurativa: treatment with ixekizumab, two case reports. Br J Dermatol. 2018;179:24–73.
   Web of Science ®Google Scholar
• Heibel MD, Heibel HD. Successful treatment of type I pityriasis rubra pilaris with ixekizumab. JAAD Case Rep. 2018;4(8):774–776.
   PubMedGoogle Scholar
• Chastagner M, Hoelt P, Kanitakis J, et al. Successful treatment of TNFα inhibitor-resistant pityriasis rubra pilaris with ixekizumab and acitretin. Eur J Dermatol. 2019;29(2):218–220.
   PubMed Web of Science ®Google Scholar
• Hanfstingl K, Pekar-Lukacs A, Motz R, et al. Successful treatment of pityriasis rubra pilaris with ixekizumab. Case Rep Dermatol. 2018;10(2):97–100.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. Bethesda (MD): National Library of Medicine. [cited 2019 Dec 11]. Available form: https://clinicaltrials.gov/
   Google Scholar
• Danesh MJ, Kimball AB. Brodalumab and suicidal ideation in the context of a recent economic crisis in the United States. J Am Acad Dermatol. 2016;74(1):190–192.
   PubMed Web of Science ®Google Scholar
• Na SY, Park MJ, Park S, et al. Up-regulation of Th17 and related cytokines in Behcet’s disease corresponding to disease activity. Clin Exp Rheumatol. 2013;31(3 Suppl 77):32–40.
   PubMed Web of Science ®Google Scholar
• Cavani A. Immune regulatory mechanisms in allergic contact dermatitis and contact sensitization. Chem Immunol Allergy. 2008;94:93–100.
   PubMedGoogle Scholar
• Ito T, Hashizume H, Shimauchi T, et al. CXCL10 produced from hair follicles induces Th1 and Tc1 cell infiltration in the acute phase of alopecia areata followed by sustained Tc1 accumulation in the chronic phase. J Dermatol Sci. 2013;69(2):140–147.
   PubMed Web of Science ®Google Scholar
• van de Kerkhof PC, Griffiths CE, Reich K, et al. Secukinumab long-term safety experience: A pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis. J Am Acad Dermatol. 2016;75(1):83–98 e4.
   PubMed Web of Science ®Google Scholar